Related Experiment Video
Updated: Apr 28, 2026

Monitoring Neuronal Survival via Longitudinal Fluorescence Microscopy
Published on: January 19, 2019
TDP-43 suppresses CGG repeat-induced neurotoxicity through interactions with HnRNP A2/B1
Fang He1, Amy Krans1, Brian D Freibaum2
1Department of Neurology, University of Michigan Medical School, 109 Zina Pitcher Pl, Ann Arbor, MI 48109, USA.
Abstract:
Nucleotide repeat expansions can elicit neurodegeneration as RNA by sequestering specific RNA-binding proteins, preventing them from performing their normal functions. Conversely, mutations in RNA-binding proteins can trigger neurodegeneration at least partly by altering RNA metabolism. In Fragile X-associated tremor/ataxia syndrome (FXTAS), a CGG repeat expansion in the 5'UTR of the fragile X gene (FMR1) leads to progressive neurodegeneration in patients and CGG repeats in isolation elicit toxicity in Drosophila and other animal models. Here, we identify the amyotrophic lateral sclerosis (ALS)-associated RNA-binding protein TAR DNA-binding protein (TDP-43) as a suppressor of CGG repeat-induced toxicity in a Drosophila model of FXTAS. The rescue appears specific to TDP-43, as co-expression of another ALS-associated RNA-binding protein, FUS, exacerbates the toxic effects of CGG repeats. Suppression of CGG RNA toxicity was abrogated by disease-associated mutations in TDP-43. TDP-43 does not co-localize with CGG RNA foci and its ability to bind RNA is not required for rescue. TDP-43-dependent rescue does, however, require fly hnRNP A2/B1 homologues Hrb87F and Hrb98DE. Deletions in the C-terminal domain of TDP-43 that preclude interactions with hnRNP A2/B1 abolish TDP-43-dependent rescue of CGG repeat toxicity. In contrast, suppression of CGG repeat toxicity by hnRNP A2/B1 is not affected by RNAi-mediated knockdown of the fly TDP-43 orthologue, TBPH. Lastly, TDP-43 suppresses CGG repeat-triggered mis-splicing of an hnRNP A2/B1-targeted transcript. These data support a model in which TDP-43 suppresses CGG-mediated toxicity through interactions with hnRNP A2/B1 and suggest a convergence of pathogenic cascades between repeat expansion disorders and RNA-binding proteins implicated in neurodegenerative disease.
Insights
TAR DNA-binding protein (TDP-43) suppresses toxic CGG repeat expansions linked to Fragile X-associated tremor/ataxia syndrome (FXTAS). This protective effect involves interactions with hnRNP A2/B1, highlighting shared pathways in neurodegenerative diseases.
Area of Science:
- Neuroscience
- Genetics
- Molecular Biology
Background:
- Nucleotide repeat expansions can cause neurodegeneration by sequestering RNA-binding proteins.
- Mutations in RNA-binding proteins can also lead to neurodegeneration by altering RNA metabolism.
- Fragile X-associated tremor/ataxia syndrome (FXTAS) involves CGG repeat expansions in the FMR1 gene, causing neurodegeneration.
Purpose of the Study:
- To investigate the role of TAR DNA-binding protein (TDP-43) in suppressing CGG repeat-induced toxicity in a Drosophila model of FXTAS.
- To elucidate the mechanism by which TDP-43 exerts its protective effects.
Main Methods:
- Utilized a Drosophila model of FXTAS to study CGG repeat toxicity.
- Examined the effects of TDP-43 and FUS co-expression on CGG repeat toxicity.
- Investigated the role of TDP-43 mutations, RNA binding, and interactions with hnRNP A2/B1 homologues (Hrb87F, Hrb98DE) in the rescue mechanism.
- Assessed the impact of TDP-43 on CGG repeat-triggered mis-splicing.
Main Results:
- TDP-43 specifically suppressed CGG repeat-induced toxicity in Drosophila.
- Disease-associated TDP-43 mutations abrogated this suppression.
- TDP-43's RNA-binding ability was not required for rescue.
- TDP-43-dependent rescue required interactions with fly hnRNP A2/B1 homologues.
- TDP-43 suppressed CGG repeat-triggered mis-splicing of an hnRNP A2/B1-targeted transcript.
Conclusions:
- TDP-43 acts as a suppressor of CGG repeat toxicity through interactions with hnRNP A2/B1.
- These findings suggest a convergence of pathogenic mechanisms between repeat expansion disorders and neurodegenerative diseases involving RNA-binding proteins.
- The study provides insights into potential therapeutic strategies targeting TDP-43 and hnRNP A2/B1 interactions.
Related Concept Videos
Drugs Affecting Neurotransmitter Synthesis
Nonsense-mediated mRNA Decay
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

